Genedata, a leading provider of in silico solutions for the pharmaceutical and life sciences industries, today announced that its Expressionist® platform has expanded GeneChip-compatible™ status for Exon expression with the Affymetrix Inc. (Nasdaq: AFFX) GeneChip® microarray platform.
Genedata Expressionist is a modular enterprise system for biomarker discovery. It represents a single-point-of-access for experimental, proprietary and public data, including sample information, raw and pre-processed transcriptomics, proteomics, metabolomics and lab chemistry data, analysis results, reports and documentation.
The Expressionist Refiner Array module performs high-throughput automated quality assessment and processing of Affymetrix GeneChip Exon data. Workflow-based processing supports validated working environments, while comprehensive reporting and documentation features ensure effective project management and communication. The high level of automation increases reproducibility and supports efficient handling of large experimental datasets, taking only a few seconds per array while scalability benchmarks demonstrate nearly linear scalability of processing 50, 100, 500 or 1,000 Exon chips at a time.
Dr. Othmar Pfannes, CEO of Genedata, said, “As a longtime Affymetrix partner, we are delighted to expand our collaboration, covering Affymetrix Exon chips. Refiner Array is an amazingly scalable solution that saves time, resources and cost in microarray analysis. The accurate processing and analysis of large datasets with high performance systems will pave the way to personalized medicine.”
“To truly understand biological systems, life scientists need to look beyond the 3’ end of a gene,” said Greg Fisher, Associate Director of Product Marketing, Systems and Software at Affymetrix. “The Affymetrix exon arrays provide a more complete and accurate view of a gene's total transcription activity compared to traditional expression array designs. The data management and analysis capabilities of Genedata’s Expressionist allow researches to make more informed decisions based on the roles alternative splicing and gene expression play in biology.”
Affymetrix GeneChip® microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases. Today, Affymetrix technology is used by the world’s top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,700 systems have been shipped around the world and more than 11,000 peer-reviewed papers have been published using the technology. Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., Cleveland, Ohio and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit: www.affymetrix.com.
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com
Marketing & Communications
Phone: +41 61 511 8459
Head of US Business
Phone: +1 650 246 3897
Fax: +1 650 246 3887
All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties relating to commercial success of the agreement with Genedata, discussed in this press release; risks of the company’s ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties related to technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties related to sole-source suppliers; risks associated with past and future acquisitions; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2006, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix’ expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
NOTE: Affymetrix, the Affymetrix logo and GeneChip® are registered trademarks owned or used by Affymetrix Inc.